Table 3 Clinical characteristics of the studied groups (incidental and symptomatic PE)

Age(M ± SD)

55.8 ± 13

54.8 ± 15

0.587

1.25

Smoking history:

  Non

3 (42.8%)

8 (47%)

1.24

1.8

  Mild

3 (42.8%)

7 (41.1%)

1.87

1.2

  Moderate

1 (14.4%)

2 (11.7%)

0.914

2.14

  Heavy

–-

––-

–-

––

Sex:

  Male

2 (28.5%)

7 (41.1%)

0.358

0.147

  Female

5 (71.5%)

10 (58.9%)

0.354

1.24

Primary site of cancer:

  Pancreas (2)

2 (100%)

–-

3.1

 ≤ 0.05

  Lung (1)

1 (100%)

–-

2.8

0.05 ≥ 

  Breast (8)

1 (12.5%)

7 (87.5%)

 − 2.6

0.05 ≥ 

  Colon (5)

1 (20%)

4 (80%)

 − 2.4

0.05 ≥ 

  Gall bladder (2)

1 (50%)

1 (50%)

0.98

1.4

  Uterus (1)

1 (100%)

–-

2.8

 ≤ 0.05

  Seminoma ad germ cell (2)

–-

2 (100%)

 − 3.1

 ≤ 0.05

  Prostate (2)

––-

2 (100%)

 − 2.9

 ≤ 0.05

  Larynx (1)

–

1 (100%)

 − 2.8

 ≤ 0.05

Stage of cancer:

  II

–-

4 (23.5%)

 − 2.7

 ≤ 0.05

  III

–-

2 (11.7%)

 − 2.4

 ≤ 0.05

  IV

7 (100%)

11 (64.8%)

2.6

 ≤ 0.05

Degree of PE:

  Massive

–

3 (17.6%)

 − 3.4

 ≤ 0.05

  Sub-massive

–-

2 (11.7%)

 − 2.5

 ≤ 0.05

  Low risk

7 (100%)

12 (70.7%)

1.3

0.654

Time of PE:

  On diagnosis

7 (100%)

2 (11.7%)

3.9

 ≤ 0.05

  On chemotherapy

–

10 (59%)

 − 3.5

 ≤ 0.05

  On hormonal therapy

–

4 (23.5%)

 − 2.87

 ≤ 0.05

  Follow up

–

1 (5.8%)

 − 2.4

 ≤ 0.05

Treatment of PE:

  Thrombolytic

–

1 (5.8%)

 − 2.4

 ≤ 0.05

  IV heparin

–

2 (11.7%)

 − 2.4

 ≤ 0.05

  LMWH

7 (100%)

15 (76.7%)

1.6

0.258

  IVC filter

–

1 (5.8%)

 − 2.1

 ≤ 0.05